Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine

and Surgery Patients With Type 2 Diabetes

A pilot, randomized, controlled study

Featured Article:

Guillermo E. Umpierrez, M.D., Roma Gianchandani, M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David H. Wesorick, M.D., Christopher Newton, M.D.,

Farnoosh Farrokhi, M.D., Limin Peng, P.H.D. David Reyes, M.D., Sangeeta Lathkar-Pradhan, M.B.B.S., Francisco Pasquel, M.D.

Diabetes Care Volume 36: 3430-3435

November, 2013

STUDY OBJECTIVE 

• To investigate the safety and efficacy of sitagliptin (Januvia) for inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

STUDY DESIGN AND METHODS

• T2D patients were randomized to receive sitagliptin alone or in combination with glargine insulin (glargine) or to a basal bolus insulin regimen (glargine and lispro) plus supplemental (correction) doses of lispro

• Major study outcomes:

• Differences in daily blood glucose (BG)• Frequency of treatment failures (defined as three or more

consecutive BG >240 mg/dL or a mean daily BG >240 mg/dL)

• Hypoglycemia between groups

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

RESULTS

• Glycemic control improved similarly in all treatment groups

• There were no differences in:

• Mean daily BG after the first day of treatment• Number of readings within a BG target of 70 and 140 mg/dL• Number of BG readings >200 mg/dL• Number of treatment failures

• Total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group

• There were no differences in length of hospital stay or in the number of hypoglycemic events between groups

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

CONCLUSIONS

• Treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435

Umpierrez G. E. et al. Diabetes Care 2013;36:3430-3435